(NASDAQ: SNDX) Syndax Pharmaceuticals's forecast annual revenue growth rate of 95.53% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 87.6%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.61%.
Syndax Pharmaceuticals's revenue in 2025 is $78,180,000.On average, 3 Wall Street analysts forecast SNDX's revenue for 2025 to be $14,745,160,944, with the lowest SNDX revenue forecast at $13,351,127,191, and the highest SNDX revenue forecast at $16,007,742,215. On average, 3 Wall Street analysts forecast SNDX's revenue for 2026 to be $34,163,862,469, with the lowest SNDX revenue forecast at $28,909,208,887, and the highest SNDX revenue forecast at $40,872,590,682.
In 2027, SNDX is forecast to generate $49,694,895,620 in revenue, with the lowest revenue forecast at $39,228,142,536 and the highest revenue forecast at $62,466,632,648.